Combined Administration of (<i>R</i>)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism

• 主要な著者: Anna Rafało-Ulińska (著者), Piotr Brański (著者), Agnieszka Pałucha-Poniewiera (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2022-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Ketamine is an effective, rapid-acting antidepressant drug (RAAD), but it induces side effects. To overcome these challenges, attempts have been made to use safer enantiomer ((<i>R</i>)-ketamine) or mGlu2/3 receptor antagonists, which induce ketamine-like effects and enhance its action....